Tigo Energy Global Quality Program Marks 1,500 Green Glove Installer Engagements
18.2.2026 12:00:00 CET | Business Wire | Press Release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s vast network of solar installers has logged 1,500 Green Glove service program engagements. The Green Glove program helps reinforce the Company’s ongoing commitment to Total Quality Solar and deliver the best possible installer experience for participants, such as Brighthouse Solar of Central California. In addition to the Green Glove program, Tigo has deployed more than 12,000 customized onboarding sequences, across ten countries, to bring new installation companies up to speed on all things Tigo. From region-specific information to product and software training tips, these sequences are designed to ensure that installers have what they need based on their company’s unique profile and location.
As the mix of technologies being deployed grows, Tigo customer programs also deliver deeper, more specialized training to help ensure systems are designed, commissioned, and serviced correctly. As a result of programs like Green Glove, customized onboarding, and Tigo Academy training, the Tigo Customer Care team has observed a 7% reduction in the number of installation-related customer support tickets per site installed with Tigo TS4 Flex MLPE from the 4th quarter of last year to the 4th quarter of this year. For Tigo EI Residential Solutions for North America and Europe, installation-related tickets per installed site have decreased by approximately 50% during the same period.
“After working with Tigo on a range of installations and system configurations leveraging the Green Glove, we absolutely believe in this program and our team has benefited significantly from it,” said Thomas Davenport, Owner and CEO at Brighthouse. “To that end, the expanded training, closer collaboration with Tigo’s technical teams, and our consistent alignment across sales, product, and support have already helped us streamline our processes and raise the bar on every subsequent installation."
With an initial focus on Commercial and Industrial (C&I) installers, the Green Glove program has helped enrich the installer journey, from design to commissioning, for both C&I as well as residential solar service companies across four continents. Launched in late 2023, the Green Glove service program began as a three-step engagement with installers to help deliver consistent improvement to customer outcomes. After more than 1,500 cases in collaboration with hundreds of Tigo installers, systems registered using the program have remained zero-issue sites.
“We have worked with dozens of solar hardware components from various manufacturers over the years, and Tigo is the only one that regularly improves how it works with installers,” said Daniel Bertinelli, Sales Director at Barbuti e Bertinelli Impianti srl. “Obviously, it is normal for product variants and lines to evolve or for power ratings to increase, but the quality of the service, support, and installer-facing engagement usually remains the same. That is not the case with Tigo, which regularly rolls out new training content, brings programs like Green Glove, and generally improves all the small interactions that occur naturally between installer and supplier.”
As solar adoption accelerates, the industry is welcoming an influx of new installation companies and technicians, with employment for solar PV installers projected to grow 42 percent from 2024 to 2034. As the industry grows, so has the network of installation companies using Tigo equipment in more than 100 countries. The growth in installers, combined with the adoption of technologies, creates a strong need for relevant, timely information on products and services. Green Glove, on-demand training through the Tigo Academy, and customized onboarding sequences are all part of a broader Tigo effort to help educate and train installers, raising the bar on total quality solar for everyone involved.
“The Green Glove program was one of the first manifestations of our embrace of the Total Quality Solar mindset, giving us a formal and documented way in which to more closely work with the many installers using Tigo products for the first time,” said James Dillon, Chief Marketing and Customer Experience Officer at Tigo. “Green Glove allows us to deepen that commitment by expanding purpose-built training, hands-on support, and cross-functional feedback loops that help installers deliver safer, faster, and more consistent system deployments.”
Installers can continue registering installations for support through the Green Glove program here. For a look at the program in real-world use, this case study highlights how Circuit Energy Solutions leveraged the Green Glove program to help ensure precise design, code compliance, and smooth commissioning across multiple commercial rooftop projects. To inquire about other Tigo solutions, contact the sales team here.
About Tigo Energy
Founded in 2007, Tigo Energy, Inc. (Nasdaq: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and provides products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218281109/en/
Contacts
Media Relations Contact:
Technica Communications
Luis de Leon
tigoenergy@technica.inc
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom